Delivering more for our investors.
Welcome to our Investor Centre. Here you’ll find important information about Avecho Ltd – a compelling investment opportunity – including ASX releases, presentations, latest news and more.
Office: Melbourne, Australia
ASX: AVE
Share Price
Investor highlights
TPM® products commercialised under license:
- Voveran® TPM Gel; Novartis, India
- Instanac® TPM Gel; Themis Medicare
- Vital ET® Biofunctional Ingredient; Ashland
- TPM® (for personal care only); Ashland
Eager to ask a question?
Click here to visit our investor hub and login to join our Q&A.
Investor Resources
Governance
| 2024 Appendix 4G and Corporate Governance Statement | 622 MB | |
| 2024 Annual Report | 1MB | |
| Remuneration and Nomination Committee Charter | 282 KB | |
| Audit and Risk Committee Charter | 254 KB | |
| Whistleblower Policy | 332 KB | |
| Board Charter | 251 KB | |
| Anti Bribery and Corruption Policy | 272 KB | |
| Shareholder Communication Policy | 193 KB | |
| 2023 Annual Report | 1 MB | |
| 2023 Appendix 4G and Corporate Governance Statement | 574 KB | |
| 2022 Appendix 4G and Corporate Governance Statement | 483 KB | |
| 2022 Annual Report | 1 MB | |
| Continuous Disclosure Policy | 226 KB | |
| Code of Conduct | 228 KB | |
| Current Constitution | 1 MB | |
| Remuneration and Nomination Committee Charter | 246 KB | |
| 2021 Appendix 4G and Corporate Governance Statement | 565 KB | |
| 2021 Annual Report | 1 MB | |
| Securities Trading Policy | 127 KB | |
| 2020 Appendix 4G and Corporate Governance Statement | 770 KB | |
| 2020 Annual Report | 778 KB | |
| 2019 Appendix 4G and Corporate Governance Statement | 423 KB |
Annual General Meeting
| Notice of Annual General Meeting 2025 | 439 KB | |
| Annual Report 31 December 2024 | 1 MB | |
| Employee Incentive Plan | 366 KB |
Investor Communications and Services
Click here to view a summary of Avecho Biotechnology’s Investor Communications and Services.
